AGP Picks
View all

Pegasys market forecast points to slower growth as hepatitis therapies shift

Nov. 9, 2026
Pegasys market forecast points to slower growth as hepatitis therapies shift
By AI, Created 14:00 UTC, Nov 09, 2026, AGP -

The Business Research Company says the Pegasys market will keep expanding through 2035, even as direct-acting antivirals pressure demand. North America led in 2025, while Asia-Pacific is projected to grow fastest as hepatitis B cases and health spending rise.

Why it matters: - Pegasys remains relevant for patients with chronic hepatitis B and C and some cancer indications, even as newer antiviral drugs reshape treatment patterns. - The market outlook matters because rising hepatitis B prevalence, healthcare spending, and access to biologic therapies can support demand in specific patient groups. - The report also signals where investors and drugmakers may see opportunity next, especially in emerging markets and oncology research.

What happened: - The Business Research Company published its Pegasys Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 9, 2026. - The report projects Pegasys market trends through 2035 and highlights historical drivers, regional growth patterns, and future product shifts. - The company included a free sample of the report and a full report page.

The details: - Pegasys is a pegylated form of interferon alfa-2a used to treat chronic hepatitis B and C infections, plus some cancers including chronic myelogenous leukemia and malignant melanoma. - The drug works by boosting immune response against viral infections and malignant cells. - Pegylation extends half-life, which allows less frequent subcutaneous injections than non-pegylated interferons. - The market grew historically on rising hepatitis infections, wider use of interferon-based therapies, clinical acceptance of pegylated interferons, and expansion of hospital antiviral programs. - Standardized treatment protocols also helped embed Pegasys in healthcare settings. - The report says Pegasys use may decline as direct-acting antivirals gain share, but demand should persist for some patient populations. - Future growth is expected to come from personalized hepatitis care, broader access programs in emerging markets, and ongoing oncology research. - Key trends include long-acting immunomodulatory therapies, fewer-dose regimens, combination antiviral treatments, advances in pegylation drug technology, and better treatment outcome monitoring. - Pegasys market demand is also linked to rising hepatitis B prevalence, which can lead to chronic liver disease, cirrhosis, and liver cancer. - The report cites hepatitis B drivers including unprotected sexual contact, intravenous drug use, and vaccination gaps in some regions. - European Centre for Disease Prevention and Control data released in April 2024 showed 28,855 hepatitis B cases across 30 EU/EEA countries in 2022, up 78% from 16,187 the year before. - The 2022 incidence rate was 8.5 cases per 100,000 population. - Higher healthcare spending is another growth support, with governments and private-sector systems expanding medical services, infrastructure, and public health programs. - UK healthcare expenditure reached about $359.16 billion (£292 billion) in 2023, up 5.6% in nominal terms, according to May 2024 statistics cited in the report. - Long-term health and social care spending in the UK rose 2.8% in real terms in 2022. - North America held the largest Pegasys market share in 2025. - Asia-Pacific is projected to be the fastest-growing regional market over the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East, and Africa. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspot infographics, and updated technology and trend analysis.

Between the lines: - The market outlook is mixed: Pegasys still has clinical utility, but its long-term growth is constrained by newer hepatitis treatments that can replace interferon-based regimens. - Regional growth appears tied to disease burden and healthcare access, which could make Asia-Pacific more important even if North America remains the largest market today. - The report leans toward a niche-but-persistent role for Pegasys rather than a broad rebound.

What's next: - Pegasys demand is likely to depend on how quickly direct-acting antivirals displace interferon-based treatment in hepatitis care. - Broader access programs and treatment expansion in emerging markets could soften the decline in some regions. - Ongoing research in oncology and improved monitoring tools may keep the product relevant in specialized use cases. - The Business Research Company is promoting additional market intelligence features in its 2026 report series, including dashboards and hotspot analysis.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

UK Post Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

UK Post Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.